May 22 (Reuters) - Japan's Otsuka Pharmaceutical said on Wednesday it will stop development of its experimental drug to treat patients with agitation associated with Alzheimer's disease. (Reporting by Mariam Sunny in Bengaluru; Editing by Maju Samuel)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6,317 JPY | -0.79% | -1.50% | +19.44% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
6,317 JPY | -0.79% | -1.50% | 21.78B | ||
2,902 JPY | -0.75% | +1.36% | 6.99B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.44% | 21.78B | |
+20.37% | 43.54B | |
+17.85% | 15.38B | |
+25.55% | 15.12B | |
+60.99% | 13.36B | |
-0.05% | 6.79B | |
-15.02% | 6.38B | |
-8.87% | 5.73B | |
+8.17% | 5.32B | |
+26.36% | 4.58B |
- Stock Market
- Equities
- 4578 Stock
- News Otsuka Holdings Co., Ltd.
- Otsuka to stop development of Alzheimer's disease drug